ES2981765T3 - Agentes pangenotípicos contra el virus de la influenza y métodos de uso de los mismos - Google Patents

Agentes pangenotípicos contra el virus de la influenza y métodos de uso de los mismos Download PDF

Info

Publication number
ES2981765T3
ES2981765T3 ES20208373T ES20208373T ES2981765T3 ES 2981765 T3 ES2981765 T3 ES 2981765T3 ES 20208373 T ES20208373 T ES 20208373T ES 20208373 T ES20208373 T ES 20208373T ES 2981765 T3 ES2981765 T3 ES 2981765T3
Authority
ES
Spain
Prior art keywords
oligonucleotide
virus
psl2
seq
lna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20208373T
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey S Glenn
Rachel Hagey
Edward Pham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Board Of Trustees Of Leland Stanfordjunior Univ
Leland Stanford Junior University
Original Assignee
Board Of Trustees Of Leland Stanfordjunior Univ
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Trustees Of Leland Stanfordjunior Univ, Leland Stanford Junior University filed Critical Board Of Trustees Of Leland Stanfordjunior Univ
Application granted granted Critical
Publication of ES2981765T3 publication Critical patent/ES2981765T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES20208373T 2016-03-02 2017-03-01 Agentes pangenotípicos contra el virus de la influenza y métodos de uso de los mismos Active ES2981765T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662302548P 2016-03-02 2016-03-02

Publications (1)

Publication Number Publication Date
ES2981765T3 true ES2981765T3 (es) 2024-10-10

Family

ID=59743201

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20208373T Active ES2981765T3 (es) 2016-03-02 2017-03-01 Agentes pangenotípicos contra el virus de la influenza y métodos de uso de los mismos

Country Status (17)

Country Link
US (1) US10597658B2 (cg-RX-API-DMAC7.html)
EP (3) EP4389221A3 (cg-RX-API-DMAC7.html)
JP (3) JP7536272B2 (cg-RX-API-DMAC7.html)
CN (1) CN108778344A (cg-RX-API-DMAC7.html)
CA (1) CA3014776A1 (cg-RX-API-DMAC7.html)
DK (1) DK3800257T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981765T3 (cg-RX-API-DMAC7.html)
FI (1) FI3800257T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240765T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066977T2 (cg-RX-API-DMAC7.html)
LT (1) LT3800257T (cg-RX-API-DMAC7.html)
PL (1) PL3800257T3 (cg-RX-API-DMAC7.html)
PT (1) PT3800257T (cg-RX-API-DMAC7.html)
RS (1) RS65707B1 (cg-RX-API-DMAC7.html)
SI (1) SI3800257T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400253T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017151795A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
WO2021201996A1 (en) * 2020-02-14 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
US12522827B2 (en) 2016-03-02 2026-01-13 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
CN115997014A (zh) * 2020-02-14 2023-04-21 小利兰·斯坦福大学董事会 抗呼吸道病毒的泛基因型药剂及其使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501843A (ja) * 1990-08-14 1994-03-03 アイシス・ファーマシューティカルス・インコーポレーテッド アンチセンスオリゴヌクレオチドによるインフルエンザa型ウイルス,アン・アーバh2n2株の阻害
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
CA2603842A1 (en) * 2005-04-08 2006-10-19 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
EP2239328A3 (en) * 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Methods and compositions for treating neurological disease
CN100562342C (zh) * 2006-01-17 2009-11-25 奥林格斯技术有限公司 防治流感病毒感染的寡核苷酸药物
WO2007084359A2 (en) * 2006-01-17 2007-07-26 Oligos Etc., Inc. Compositions and methods for the treatment of influenza infection
AU2007310982A1 (en) * 2006-10-18 2008-04-24 Marina Biotech, Inc. Nicked or gapped nucleic acid molecules and uses thereof
US20090042823A1 (en) 2007-08-10 2009-02-12 Mdrna, Inc. Uses of broad spectrum rnai therapeutics against influenza
US20120003156A1 (en) 2008-07-01 2012-01-05 The Johns Hopkins University Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
SI2607484T1 (sl) 2008-10-27 2016-11-30 Biomarin Technologies B.V. Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
AU2010319314C1 (en) * 2009-11-13 2016-09-01 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
US8921334B2 (en) 2009-12-29 2014-12-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
CN103118694B (zh) 2010-06-01 2016-08-03 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现

Also Published As

Publication number Publication date
EP3423107A1 (en) 2019-01-09
WO2017151795A1 (en) 2017-09-08
HRP20240765T1 (hr) 2024-09-13
JP2019511471A (ja) 2019-04-25
HUE066977T2 (hu) 2024-09-28
PL3800257T3 (pl) 2024-09-16
SI3800257T1 (sl) 2025-04-30
US20190136242A1 (en) 2019-05-09
DK3800257T3 (da) 2024-06-24
JP2025096365A (ja) 2025-06-26
JP7536272B2 (ja) 2024-08-20
LT3800257T (lt) 2024-07-25
CN108778344A (zh) 2018-11-09
CA3014776A1 (en) 2017-09-08
RS65707B1 (sr) 2024-08-30
EP3800257B1 (en) 2024-05-01
US10597658B2 (en) 2020-03-24
PT3800257T (pt) 2024-06-26
SMT202400253T1 (it) 2024-09-16
EP4389221A2 (en) 2024-06-26
EP4389221A3 (en) 2024-11-20
FI3800257T3 (fi) 2024-06-19
EP3423107A4 (en) 2020-01-15
EP3800257A1 (en) 2021-04-07
JP2022176378A (ja) 2022-11-25

Similar Documents

Publication Publication Date Title
Steinhauer et al. Genetics of influenza viruses
Hutchinson et al. Genome packaging in influenza A virus
Hagey et al. Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2
Naffakh et al. Host restriction of avian influenza viruses at the level of the ribonucleoproteins
JP2025096365A (ja) インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
Szabat et al. RNA secondary structure as a first step for rational design of the oligonucleotides towards inhibition of influenza a virus replication
Schrauwen et al. Insertion of a multibasic cleavage site in the haemagglutinin of human influenza H3N2 virus does not increase pathogenicity in ferrets
Dupré et al. Phylodynamic study of the conserved RNA structure encompassing the hemagglutinin cleavage site encoding region of H5 and H7 low pathogenic avian influenza viruses
JP7863883B2 (ja) 呼吸器ウイルスに対する汎遺伝子型薬剤及びそれを使用する方法
Verity et al. Rapid generation of pandemic influenza virus vaccine candidate strains using synthetic DNA
US12522827B2 (en) Pan-genotypic agents against influenza virus and methods of using the same
Chiang et al. Mutations at alternative 5′ splice sites of M1 mRNA negatively affect influenza A virus viability and growth rate
US12618063B2 (en) Pan-genotypic agents against influenza virus and methods of using the same
HK40113249A (en) Pan-genotypic agents against influenza virus and methods of using the same
EP4464779A2 (en) Pan-genotypic agents against respiratory viruses and methods of using the same
AU2024341512A1 (en) Agents against respiratory viruses and methods of using the same
HK40118855A (en) Pan-genotypic agents against respiratory viruses and methods of using the same
Hagey et al. Identification and targeting of a pan-genotypic influenza A virus RNA structure that mediates packaging and disease
HK40091735A (en) Pan-genotypic agents against respiratory viruses and methods of using the same
HK1262033A1 (en) Pan-genotypic agents against influenza virus and methods of using the same
US11046958B2 (en) Antisense oligonucleotides that inhibit influenza virus replication and uses thereof
Winn The role of host factor Transportins in Influenza virus entry and infection
Braun-Hagey Viral RNA Secondary Structures: Novel Biology and Therapeutic Implications